Compare Commvault Systems Inc (CVLT) vs Cytokinetics Inc (CYTK) Price & Performance

Commvault (CVLT) trades at $148.65, down 1.28% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.28 exceeding the $1.09 estimate, though Q3 2025 missed expectations. Revenue reached $995.62 million in 2025, with a net income margin of 5.97%. However, valuation ratios are elevated, including a P/E of 94.03 and P/B of 821.14, indicating high growth expectations. Recent news highlights multiple class-action lawsuits with a July 17, 2026 deadline, adding legal overhangs.

The outlook for CVLT is mixed, with solid profitability and analyst buy ratings (54.55% consensus) supporting upside to the $155.00 high target, but risks from the lawsuits and rich valuations could pressure the stock. Investors should weigh robust cash flow growth in 2026 against potential legal and competitive headwinds in the data protection sector.

CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.

Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.